Cenobamate Helped Many Children With Hard-To-Treat Epilepsy

What was studied

This study looked at cenobamate, a seizure medicine, used "off label" in children and teens with drug-resistant epilepsy. "Off label" means the medicine was used in an age group or situation that is not the standard approved use. The study included 108 patients from several centers in Europe. Their median age was about 13.8 years, with ages ranging from 3.9 to 19.8 years.

The researchers reviewed past medical records rather than assigning treatment in a planned trial. They looked at how well cenobamate worked, what side effects were reported, how long patients stayed on it, and whether other anti-seizure medicines could be reduced. Follow-up lasted a median of about 582 days, although some patients were followed for a much shorter time.

What they found

About 53% of patients had their seizures reduced by at least half. About 19% were seizure-free during the documented interval between visits. The median number of seizures per month fell from 30 to 9.

Many patients had reductions in other seizure medicines: doses of other anti-seizure medicines were reduced in 44% of patients, and other medicines were discontinued in 51%. The median number of anti-seizure medicines went from 3 to 2.

Side effects were reported in 57.4% of patients. The most common were fatigue, vertigo, and behavior-related symptoms. No cases of DRESS were reported. At 12 months, 86.8% of patients were still taking cenobamate, and retention was higher in patients who did not have side effects.

Limits of the evidence

This was a retrospective study, so it looked back at records instead of testing the drug in a randomized, controlled way. That means it cannot show with certainty that cenobamate alone accounted for the seizure improvement.

There was no comparison group, and patients were also taking other anti-seizure medicines, some of which were changed during treatment. Follow-up length varied, and some patients had short follow-up. The study also reports seizure freedom only during the documented interval between visits, so it does not show long-term seizure freedom for everyone.

Because this was off-label real-world use in specialized centers, the results may not apply to every child with epilepsy.

For families and caregivers

For families facing drug-resistant epilepsy, this study suggests cenobamate may help some children and teens when other medicines have not worked well. In this group, more than half had a meaningful drop in seizures, and some had reductions in the number or dose of other seizure medicines.

At the same time, side effects were common, and this study cannot show how well the medicine would work compared with other options. The results are encouraging, but stronger studies are still needed to better understand safety, dosing, and which children are most likely to benefit.

What to watch next

Prospective controlled studies in children are needed, and families can ask a clinician how off-label cenobamate is monitored for side effects and medicine interactions.

Terms in this summary

drug-resistant epilepsy

Epilepsy that does not come under good control after trying standard seizure medicines.

off label

Use of a medicine in a way that is not the standard approved use, such as in a different age group.

adjunctive treatment

A treatment added on to other treatments, rather than used alone.

retrospective study

A study that looks back at existing medical records or past events.

retention

How many patients keep taking a treatment over time.

anti-seizure medicine

A medicine used to prevent or reduce seizures.

DRESS

A rare but serious drug reaction that can cause rash, fever, and organ problems.

vertigo

A spinning or dizzy feeling.